Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

摘要: Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 the JAK-STAT signaling pathway, being developed by Incyte Corp Novartis AG. was initially to target constitutive activation pathway in patients with myeloproliferative neoplasms (MPNs). Meaningful reductions spleen size constitutional symptoms have been noted myelofibrosis (both primary post-essential thrombocythemia/polycythemia vera). Data from phase I/II clinical trial led ongoing registration trials US Europe. Toxicity (primarily decreased erythropoiesis thrombocytopoiesis) has managed close control dosing. The inhibition inflammatory cytokine through intriguing results rheumatoid arthritis psoriasis (using topical cream formulation). well tolerated, first-in-class various potential indications.